{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:35Z","timestamp":1786122095377,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04412-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:03:42Z","timestamp":1780535022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the evidence gap: three-year BCG maintenance therapy shows enhanced protection over one-year regimen in Chinese NMIBC"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiang","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"6","key":"4412_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-a summary of the 2024 guidelines update. Eur Urol. 2024;86(6):531\u201349.","journal-title":"Eur Urol"},{"key":"4412_CR2","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, et al. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743.","journal-title":"BMJ"},{"issue":"5","key":"4412_CR3","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"key":"4412_CR4","doi-asserted-by":"crossref","unstructured":"B\u00f6hle A, Bock PR. Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682\u20136; discussion 686\u20137.","DOI":"10.1016\/j.urology.2003.11.049"},{"issue":"3","key":"4412_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372.","journal-title":"Eur Urol"},{"issue":"5","key":"4412_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, et al. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial \u201cNIMBUS.\u201d Eur Urol. 2020;78(5):690\u20138.","journal-title":"Eur Urol"},{"issue":"2","key":"4412_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Mart\u00ednez-Pi\u00f1eiro","year":"2015","unstructured":"Mart\u00ednez-Pi\u00f1eiro L, et al. Maintenance therapy with 3-monthly Bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO Study 98013. Eur Urol. 2015;68(2):256\u201362.","journal-title":"Eur Urol"},{"issue":"6","key":"4412_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4111\/icu.20230161","volume":"64","author":"A El Azab","year":"2023","unstructured":"El Azab A, et al. The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Gu\u00e9rin versus BCG alone in non-muscle-invasive bladder cancer: a randomized controlled trial. Investig Clin Urol. 2023;64(6):554\u201360.","journal-title":"Investig Clin Urol"},{"key":"4412_CR9","doi-asserted-by":"crossref","unstructured":"Claps F, et al. BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. Int J Mol Sci. 2023;24(16):12596.","DOI":"10.3390\/ijms241612596"},{"issue":"1","key":"4412_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"1","key":"4412_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38\u201340.","journal-title":"J Urol"},{"issue":"4","key":"4412_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"2","key":"4412_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247\u201356.","journal-title":"Eur Urol"},{"issue":"3","key":"4412_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley MD, et al. A systematic review of intravesical Bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209\u201316.","journal-title":"BJU Int"},{"issue":"6","key":"4412_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical Bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216\u201323.","journal-title":"Urology"},{"issue":"4","key":"4412_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley MD, et al. Intravesical Bacillus Calmette-Gu\u00e9rin is superior to Mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485\u201390.","journal-title":"BJU Int"},{"issue":"1","key":"4412_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90\u20135.","journal-title":"J Urol"},{"issue":"5","key":"4412_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of Epirubicin, Bacillus Calmette-Gu\u00e9rin, and Bacillus Calmette-Gu\u00e9rin plus Isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373.","journal-title":"Eur Urol"},{"issue":"2","key":"4412_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.36469\/jheor.2024.124208","volume":"11","author":"FD Gaylis","year":"2024","unstructured":"Gaylis FD, et al. Adherence to First-Line Intravesical Bacillus Calmette-Gu\u00e9rin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer. J Health Econ Outcomes Res. 2024;11(2):109\u201317.","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"4412_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.acuro.2022.06.001","volume":"47","author":"P Verri","year":"2023","unstructured":"Verri P, et al. Reduced- vs full-dose BCG in bladder cancer: a systematic review and meta-analysis. Actas Urol Esp (Engl Ed). 2023;47(1):4\u201314.","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"3","key":"4412_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm BE, et al. Efficacy of Bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol. 2017;198(3):503\u201310.","journal-title":"J Urol"},{"issue":"2","key":"4412_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/curroncol31020079","volume":"31","author":"S Lidagoster","year":"2024","unstructured":"Lidagoster S, et al. BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer. Curr Oncol. 2024;31(2):1063\u201378.","journal-title":"Curr Oncol"},{"key":"4412_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S202006","volume":"9","author":"S Guallar-Garrido","year":"2020","unstructured":"Guallar-Garrido S, Juli\u00e1n E. Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1\u201311.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"4412_CR24","first-page":"13","volume":"77","author":"A Artiles Medina","year":"2025","unstructured":"Artiles Medina A, et al. Clinical outcomes of BCG infections in patients undergoing intravesical immunotherapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Minerva Urol Nefrol. 2025;77(1):13\u201324.","journal-title":"Minerva Urol Nefrol"},{"issue":"11","key":"4412_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/iju.15263","volume":"30","author":"M Miyake","year":"2023","unstructured":"Miyake M, et al. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: evidence update of surgical concept, risk stratification, and BCG-treated disease. Int J Urol. 2023;30(11):944\u201357.","journal-title":"Int J Urol"},{"issue":"2","key":"4412_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","volume":"6","author":"IJ Beijert","year":"2023","unstructured":"Beijert IJ, et al. Prognosis of primary papillary Ta grade 3 bladder cancer in the non-muscle-invasive spectrum. Eur Urol Oncol. 2023;6(2):214\u201321.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"4412_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00345-025-06089-z","volume":"43","author":"E Rinderknecht","year":"2025","unstructured":"Rinderknecht E, et al. Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomy. World J Urol. 2025;43(1):705.","journal-title":"World J Urol"},{"issue":"5","key":"4412_CR28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/bju.16828","volume":"136","author":"M Ferro","year":"2025","unstructured":"Ferro M, et al. Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer. BJU Int. 2025;136(5):882\u201390.","journal-title":"BJU Int"},{"issue":"4","key":"4412_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.euo.2025.04.010","volume":"8","author":"R Contieri","year":"2025","unstructured":"Contieri R, et al. Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. 2025;8(4):977\u201385.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"4412_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bju.15984","volume":"132","author":"F Claps","year":"2023","unstructured":"Claps F, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023;132(2):170\u201380.","journal-title":"BJU Int"},{"issue":"3","key":"4412_CR31","first-page":"338","volume":"77","author":"M Ferro","year":"2025","unstructured":"Ferro M, et al. Assessing the influence of smoking on inflammatory markers in bacillus Calmette Gu\u00e9rin response among bladder cancer patients: a novel machine-learning approach. Minerva Urol Nefrol. 2025;77(3):338\u201346.","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"4412_CR32","doi-asserted-by":"publisher","first-page":"189.e1","DOI":"10.1016\/j.urolonc.2024.11.015","volume":"43","author":"R Contieri","year":"2025","unstructured":"Contieri R, et al. Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy. Urol Oncol. 2025;43(3):189.e1-189.e8.","journal-title":"Urol Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04412-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:49:52Z","timestamp":1786088992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04412-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04412-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol for this research project was approved by the institutional review board of Nanjing Drum Tower Hospital. Owing to the retrospective nature of the study, informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}